Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention

Digestive Diseases and Sciences

Volumn 58, Issue 9, 2013, Pages 2615-2622

  Fink, Stephen P ^a,b   Yang, Dong Hoon ^c   Barnholtz Sloan, Jill S ^b   Ryu, Yeon Mi ^c   Mikkola, Debra ^a,b   Potter, John D ^d,e   Lampe, Johanna W ^d   Markowitz, Sanford D ^a,b   Myung, Seung Jae ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c University of Ulsan   (South Korea)

^d Fred Hutchinson Cancer Research Center   (United States)

^e MASSEY UNIVERSITY   (New Zealand)

Author keywords

15 PGDH; Biomarker; Colon cancer; NSAIDs

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COLON BIOPSY; COLON TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ASPIRIN; CHEMOPREVENTION; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECTUM; RNA, MESSENGER;

EID: 84884207640     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2670-5     Document Type: Article

References (22)

1. Markowitz SD, Dawson DM, Willis J, et al. Focus on colon cancer. Cancer Cell. 2002;1:233-236.
2. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101-128.
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
4. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280:3217-3223.
5. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA. 2006;103:12098-12102.
6. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA. 2004;101:17468-17473.
7. Yan M, Myung SJ, Fink SP, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA. 2009;106:9409-9413.
8. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-895.
9. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
10. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-884.
11. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
12. Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106:1564-1570.
13. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081-2087.
14. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-178.
15. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
16. Chan CW, Wong NA, Liu Y, et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci USA. 2009;106:1936-1941.
17. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
18. Williamson SL, Kartheuser A, Coaker J, et al. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis. 1999;20:805-810.
19. Markowitz SD. Aspirin and colon cancer-targeting prevention? N Engl J Med. 2007;356:2195-2198.
20. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-1682.
21. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
22. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.